Hayo Therapeutics SASwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Tag Archive for: Lilly
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.